Bloomin Brands Eyes Turnaround After Languishing Stock
Cash vs Investing: Lessons from 2010's Recovery Year
Insurance Stocks Rally as Bill Heads to Lok Sabha
Bank of America Trims Oracle's Stock-Price Target to $21.30
Global Stocks Decline Ahead of Key Data Releases and Central-Bank Meetings
Global Markets Edge Lower Amid Uncertainty Ahead of U.S. CPI Release
Investopedia Identifies Six Internet Stocks Set to Dominate 2025
Evercore Downgrades Nordstrom to Hold Amid Rising Inventory and Margin Pressures
Stocks vs. Homes: Which is the Better Investment?
Nikkei Gains 0.8% on Tech Earnings Surge
Investors Seek New Growth Avenues After $30B Big-Tech Sell-off
The Forever Portfolio 2026 Refresh: 3 Stocks to Buy and 3 to Sell
Oracle's Share Price Dip Is Temporary - What the Numbers Really Say
Dam Capital Shares Plunge Over 50% from Listing Peak as Key Dealmakers Exit
Asian Shares Slip Amid Inflation, U.S. Rate Hikes, and China Growth Concerns
Ultra-High-Yield Stock Kings: Top Picks for 2026 Passive Income
Global Funds Shift to Indian Stocks as AI Risk Hedge
Meta Shares Surge 7 % After $30 Billion Metaverse Cut-Back
Alphabet's Bull vs. Bear Narrative: What Investors Should Know
Motley Fool Launches Active-Style ETFs Offering Managed Growth Exposure
Ellington Financial's Preferred Shares Outperform MRIT on Risk-Adjusted Returns
Chewy Posts 20% YoY Revenue Growth in Q2 2024
Build-a-Bear Faces Potential 10-15% Tariff Hike on Plush Fabrics
Nebius (NEBI): Late-Stage Biotech Aims to Break Blood-Brain Barrier with Neuro-Oncology Pipeline
U.S. Markets Slide on Energy and Tech Declines
Investing in the Stock Market in 2026: Historical Trends and Future Outlook
Is It Too Late to Buy AI Stocks in 2025? Motley Fool's Take
UiPath Q3 Highlights: Revenue Growth Amidst Margin Compression
Locale: UNITED STATES

Summary of “UiPath Q3: This Is Not the AI or Robotics Stock to Buy Now” (Seeking Alpha)
Published by Seeking Alpha, accessed 15 Dec 2025
1. Executive Overview
The article provides a skeptical take on UiPath (NYSE: UPA) after its Q3 earnings release. While the company continues to grow its revenue, the author argues that the growth is slowing, margins are under pressure, cash burn remains high, and the valuation remains stretched in light of a crowded RPA market and the arrival of generative‑AI competitors. The recommendation is a “Hold” or “Sell” – in short, “Not a buy right now.”
2. Q3 2024 Results at a Glance
| Metric | Q3 2024 | YoY Change | Consensus Estimate |
|---|---|---|---|
| Revenue | $112 m | +18 % | $110 m |
| Gross Margin | 36 % | Down from 38 % Q2 | 38 % |
| Operating Expense | $58 m | Up 12 % | $52 m |
| Net Loss | $43 m | Down from $56 m | $50 m |
| Cash Burn | $45 m | Up 5 % | $40 m |
Key Takeaway: Revenue growth is still positive, but the margin squeeze and escalating operating expense are eroding profitability.
The article cites the company’s earnings call transcript (link to the SEC filing) for the exact figures, noting that while revenue topped expectations, the declining gross margin and surging R&D spend are cause for concern.
3. Why the Author Says “Not a Buy”
3.1 Margin Compression
- UiPath’s gross margin fell to 36 % from 38 % in Q2, primarily due to higher cloud infrastructure costs and a shift toward higher‑cost AI‑enhanced solutions.
- The article links to a market‑analysis blog that explains how many RPA firms are pricing similar AI features, driving a price‑war.
3.2 Escalating Operating Expenses
- Operating expenses grew 12 % to $58 m, with R&D spending outpacing revenue growth.
- The author references a Bloomberg piece that lists several competitors (Blue Prism, Automation Anywhere) also increasing R&D outlays, implying a “cost spiral” across the industry.
3.3 Cash Burn & Funding Pressure
- The company burned $45 m of cash, slightly above the $40 m burn forecast.
- A link to a Seeking Alpha article on “RPA Cash Burn” highlights that many peers need fresh capital to sustain their AI roadmaps, potentially diluting shareholders.
3.4 Valuation Concerns
- UiPath trades at a P/S ratio of ~14x, compared to ~8x for Blue Prism and ~6x for Automation Anywhere.
- The author points to a CNBC article that discusses the “AI hype” inflating RPA valuations, and a Wall Street Journal commentary on the risk of “over‑valuation in the tech sector.”
3.5 Competitive & Market Risks
- The author links to an Inc. article that outlines the generative‑AI wave (e.g., OpenAI’s GPT‑4) and how it could replace many “rule‑based” RPA solutions.
- There is a note that UiPath’s strategy of integrating AI into its RPA engine may not be enough to keep it ahead of cheaper, low‑code platforms such as Microsoft Power Automate.
4. The Company’s Narrative vs. Reality
Company Narrative: UiPath’s management emphasizes a “RPA‑first, AI‑next” strategy, positioning the company as the market leader with a vast customer base in banking, insurance, and manufacturing.
Author’s Counterpoint:
- Revenue Concentration: About 40 % of revenue comes from a handful of “enterprise” customers. A single client loss could materially affect earnings.
- Execution Risk: The article cites a Financial Times report on a major partner’s shift to a competitor’s platform, illustrating the vulnerability of UiPath’s sales pipeline.
- Integration Challenges: The author references a TechCrunch piece on the difficulty of merging AI with legacy RPA workflows, suggesting a longer‑term ramp‑up than the company’s guidance implies.
5. Guidance & Outlook
5.1 Q4 Guidance
- Revenue: $115–$118 m (a 6–8 % YoY increase) – lower than analysts’ 12 % projection.
- Gross Margin: 35 % – a continued decline.
5.2 Fiscal 2025 Outlook
- Revenue CAGR: 22 % – the author argues this is “optimistic” given current margin trends.
- EBITDA: Projected to remain negative, with the company continuing to “operate at a loss” until 2026.
The article links to the official earnings presentation PDF, where the company outlines its roadmap but fails to address the margin compression in detail.
6. Bottom‑Line Recommendation
“Hold or Sell.”
The author concludes that the stock is overpriced relative to its fundamentals, especially when compared to peers with stronger margin profiles and lower burn rates. He advises investors to either wait for a market correction or seek value in more mature RPA companies.
7. Additional Context from Follow‑Up Links
| Link | Context | Key Insight |
|---|---|---|
| Seeking Alpha “RPA Cash Burn” article | Explains industry cash burn trends | Many RPA firms face similar burn; UiPath’s burn is among the highest. |
| Bloomberg “RPA R&D Spree” | Discusses competitive R&D spending | RPA firms are investing heavily in AI to stay ahead. |
| CNBC “AI Hype & Valuations” | Discusses AI overvaluation across tech | Supports the argument that UiPath’s valuation may be inflated. |
| Inc. “Generative AI Disruption” | Overview of generative‑AI threat | Highlights risk that RPA may be replaced by generative AI. |
| TechCrunch “AI‑RPA Integration Challenges” | Discusses technical integration hurdles | Supports the view that UiPath’s AI roadmap may be more difficult than expected. |
8. Final Thoughts
While UiPath remains a major player in the RPA ecosystem, the article underscores a number of red flags: margin squeeze, high operating expenses, persistent cash burn, and an over‑valued market cap in the face of increasing competition and technological disruption. For investors looking for exposure to automation, the author suggests waiting for a more favorable valuation or turning to competitors with tighter cost controls. The article serves as a cautionary tale that not all “AI” or “robotics” headlines translate into attractive, sustainable investment opportunities.
Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/article/4853312-uipath-q3-this-is-not-the-ai-or-robotics-stock-to-buy-now ]
Tesla's Production and Delivery Numbers Show Strong 12% YoY Growth
UiPath: Should Investors Buy RPA Stock Before 2026?
Opendoor Stock: Is It Worth the Investment?
Lyft's 2026 Outlook: EV Adoption & Autonomous Break-Even
Tilray Brands Stock Slides 66% From 2025 Peak - Investors Brace for Regulatory Headwinds
C3.ai Faces Tough Recovery but Remains Worth Holding
Is Now the Time to Buy UiPath Stock Before the 2026 Series C Funding?
Terawulf's Share Price Dip Is a Market Overreaction, Not a Fundamental Shock